NASDAQ:NVLN Novelion Therapeutics (NVLN) Stock Price, News & Analysis → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free NVLN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.68▼$0.7052-Week Range N/AVolume26,947 shsAverage Volume190,529 shsMarket Capitalization$13.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Novelion Therapeutics alerts: Email Address Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Novelion Therapeutics Stock (NASDAQ:NVLN)Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Read More Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. NVLN Stock News HeadlinesJune 2, 2023 | finance.yahoo.comCYTO - Altamira Therapeutics Ltd.See More Headlines Receive NVLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novelion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2019Today5/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVLN CUSIPN/A CIK827809 Webwww.novelion.com Phone617-500-7867FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,330,000.00 Net Margins-79.43% Pretax MarginN/A Return on EquityN/A Return on Assets-26.13% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.21 Sales & Book Value Annual Sales$130.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($4.69) per share Price / BookN/AMiscellaneous Outstanding Shares19,619,000Free FloatN/AMarket Cap$13.77 million OptionableOptionable Beta2.12 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Benjamin S. Harshbarger (Age 50)Interim CEO, Gen. Counsel & Corp. Sec. Mr. Michael D. Price (Age 61)Exec. VP & CFO Mr. Roger W. Louis (Age 63)Global Chief Compliance Officer and Head of R&D Ms. Barbara Y. Chan (Age 55)VP & Chief Accounting Officer Ms. Amanda MurphyDirector of Investor Relations & Corp. CommunicationsKey CompetitorsPieris PharmaceuticalsNASDAQ:PIRSAvalo TherapeuticsNASDAQ:AVTXRedHill BiopharmaNASDAQ:RDHLMonopar TherapeuticsNASDAQ:MNPRKiora PharmaceuticalsNASDAQ:KPRXView All Competitors NVLN Stock Analysis - Frequently Asked Questions How were Novelion Therapeutics' earnings last quarter? Novelion Therapeutics Inc. (NASDAQ:NVLN) issued its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to analyst estimates of $40.90 million. What other stocks do shareholders of Novelion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Amicus Therapeutics (FOLD), Applied Genetic Technologies (AGTC), Advanced Micro Devices (AMD), Biocept (BIOC), Karyopharm Therapeutics (KPTI), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and Actinium Pharmaceuticals (ATNM). This page (NASDAQ:NVLN) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novelion Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.